MSI2 and chronic myelogenous leukemia, BCR-ABL1 positive: Elevated MSI2 expression is considered a biomarker of poor outcome in multiple hematological diseases, such as chronic myeloid leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic lymphocytic leukemia (CLL)14,15,19,51–53.